This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM,...
-
Upload
marsha-mitchell -
Category
Documents
-
view
217 -
download
1
Transcript of This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM,...
![Page 1: This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive.](https://reader036.fdocuments.us/reader036/viewer/2022062517/56649ef45503460f94c07bc1/html5/thumbnails/1.jpg)
This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092
Slideshow ProjectDOI:10.1682/JRRD.2013.04.0092JSP
Proposed comprehensive ototoxicity monitoring program for VA
healthcare (COMP-VA)
Dawn Konrad-Martin, PhD; Kelly M. Reavis, MPH; Garnett McMillan, PhD; Wendy J. Helt, MA; Marilyn Dille, PhD
![Page 2: This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive.](https://reader036.fdocuments.us/reader036/viewer/2022062517/56649ef45503460f94c07bc1/html5/thumbnails/2.jpg)
This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092
Slideshow ProjectDOI:10.1682/JRRD.2013.04.0092JSP
• Aim– Describe COMP-VA, a comprehensive ototoxicity
monitoring program developed for VA patients receiving cisplatin.
• Relevance– With improved survivability following cancer
treatment, Veterans treated with cisplatin have dual goals of effective treatment and preserved quality of life.
![Page 3: This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive.](https://reader036.fdocuments.us/reader036/viewer/2022062517/56649ef45503460f94c07bc1/html5/thumbnails/3.jpg)
This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092
Slideshow ProjectDOI:10.1682/JRRD.2013.04.0092JSP
Method• COMP-VA is designed to be
administered on chemo-therapy treatment unit just before treatment (chairside). – Uses portable ototoxicity
identification device (OtoID) that can provide reliable and accurate hearing thresholds on hospital ward during treatment.
![Page 4: This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive.](https://reader036.fdocuments.us/reader036/viewer/2022062517/56649ef45503460f94c07bc1/html5/thumbnails/4.jpg)
This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092
Slideshow ProjectDOI:10.1682/JRRD.2013.04.0092JSP
Clinical Objectives• Pretreatment ototoxicity risk assessment.• Behavioral screening for early hearing changes.• Screening for outer hair cell dysfunction.• Nonbehavioral screening for early hearing changes.• Screen failure follow-up testing.• Screening for tinnitus.• Patient and provider education about ototoxic-induced
hearing and tinnitus, synergistic effects of ototoxins and noise overexposure, and rehabilitative solutions to hearing loss and tinnitus.
![Page 5: This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive.](https://reader036.fdocuments.us/reader036/viewer/2022062517/56649ef45503460f94c07bc1/html5/thumbnails/5.jpg)
This article and any supplementary material should be cited as follows: Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1):x–x. http://dx.doi.org/10.1682/JRRD.2013.04.0092
Slideshow ProjectDOI:10.1682/JRRD.2013.04.0092JSP
Conclusion
• Using evidence-based behavioral and objective test protocols, COMP-VA provides up-to-the-minute estimates of ototoxicity before patient’s next treatment.– This allows for timely consideration of treatment
changes.
• Program encourages efficient communication and team relationships between audiology and oncology.